San Donato Hospital
Hodgkin's lymphoma treatment cost in Italy typically includes diagnostic staging like bone marrow puncture with cytogenetic analysis, which runs from $700 to $1,300. Primary treatments such as chemotherapy range from $3,500 to $7,500, while immunotherapy with Keytruda costs between $22,000 and $32,000. Total expenses depend on the disease stage and treatment cycles. Patients often save 30-50% compared to US costs. Milan remains the top destination for this care.
Typical Hodgkin's Lymphoma Treatment Costs in Italy
Bookimed Expert Insight: Advanced cases requiring specialized care benefit most from centers like San Raffaele in Milan. Dr. Fabio Ciceri leads their hematology unit, specializing in cell and gene therapy clinical trials. This clinic is recognized as one of the world's best hospitals by Newsweek. It offers high-value care for patients needing complex stem cell therapies. Multidisciplinary teams here integrate research with patient treatment for better outcomes.
| Włochy | Turcja | Austria | |
| Terapia biologiczna | od $18,000 | od $5,500 | od $20,000 |
| Radioterapia raka odbytnicy | od $7,000 | od $7,000 | od $12,000 |
| Immunoterapia Keytruda (Pembrolizumab) | od $22,000 | od $3,300 | od $15,000 |
| Chemioterapia w raku piersi | od $4,500 | od $1,200 | od $15,000 |
| Chemioterapia | od $3,500 | od $2,430 | od $2,500 |
Państwo nie płacą za usługi Bookimed. Ceny leczenia choroby hodgkina odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w leczeniu choroby Hodgkina. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas leczenia choroby Hodgkina.
Kierownik Oddziału Hematologii i Transplantacji Szpiku Kostnego w klinice San Raffaele — profesor Ciceri kieruje badaniami klinicznymi w zakresie terapii komórkowej i genowej nowotworów hematologicznych.
Lekarz pełni funkcję zastępcy dyrektora oddziału hematologii i onkologii oraz dyrektora jednostki chłoniaków w Instytucie Naukowym San Raffaele, koncentrując się na leczeniu chłoniaków. <\/p>
Jest założycielem Włoskiej Fundacji Chłoniaków, poświęconej rozwijaniu badań klinicznych w zarządzaniu chłoniakami. <\/p>
Jego wykształcenie akademickie obejmuje stopień naukowy w zakresie medycyny ogólnej i chirurgii z Uniwersytetu w Buenos Aires i Uniwersytetu w Parmie oraz specjalizację w onkologii medycznej z Uniwersytetu w Mediolanie. <\/p>
Lekarz jest autorem ponad 300 prac na temat leczenia chłoniaków i członkiem kilku prestiżowych towarzystw hematologicznych i onkologicznych.<\/p>
The standard first-line chemotherapy for Hodgkin lymphoma in Italy is the ABVD regimen. Clinics like San Raffaele utilize this protocol as the primary treatment for both early and advanced stages. It consists of Adriamycin, Bleomycin, Vinblastine, and Dacarbazine administered in 28-day cycles.
Bookimed Expert Insight: Italian research hospitals like San Raffaele integrate research directly into clinical care through IRCCS accreditation. Professor Fabio Ciceri at San Raffaele oversees specialized units focusing on oncohematology. Data shows these academic centers prioritize PET-adapted strategies. This allows for precision de-escalation of drugs like Bleomycin to ensure long-term health.
Patient Consensus: Patients note it is essential to discuss fertility preservation before starting the first cycle. Many emphasize verifying if the treatment plan will be adjusted based on the initial PET scan results.
Italian centers treat relapsed Hodgkin lymphoma by achieving deep remission before autologous stem cell transplantation. Specialists utilize salvage regimens like IGEV or targeted biological therapies. Eligible patients then proceed to high-dose chemotherapy supported by stem cell rescue to ensure long-term survival.
Bookimed Expert Insight: Italian hematology excels because major centers like San Raffaele also function as leading research hubs. Dr. Fabio Ciceri leads the unit there. He serves as a principal investigator in cell and gene therapy trials. This dual focus means patients access advanced protocols and clinical trials early. Treatment at such high-volume centers often provides better access to emerging immunotherapy combinations.
Patient Consensus: Patients emphasize the importance of reaching a clear PET scan after salvage therapy. They note that specialized transplant centers are the best for managing complex cases.
IRCCS Ospedale San Raffaele and Istituto Nazionale dei Tumori in Milan are the leading hospitals for complex Hodgkin's lymphoma. These Ministry of Health-accredited research institutes offer cellular therapies and high-volume stem cell transplants. They specialize in treating relapsed or refractory cases using precision hematology protocols.
Bookimed Expert Insight: Data shows Milan is Italy's primary hub for hematology. San Raffaele stands out because it treats 300,000 patients annually and pioneered the world's first stem cell gene therapy. For complex cases, choosing a high-volume center is vital because they manage more salvage treatments and complex transplants than smaller regional clinics.
Patient Consensus: Patients emphasize finding a dedicated hematology team rather than general oncology for difficult cases. They note that infrastructure in northern Italy offers better access to advanced clinical trials and specialized transplant units.
Italy recognized lymphoma specialists include Dr. Fabio Ciceri at San Raffaele and Professor Andres Ferreri. These experts utilize multidisciplinary boards at JCI-accredited research hospitals. Key centers focus on advanced therapies like immunotherapy and stem cell transplants. Italian protocols follow national standards for high-precision diagnostic accuracy.
Bookimed Expert Insight: San Raffaele handles over 300,000 patients annually and performs the largest volume of complex procedures. Choosing specialists here means joining a system that pioneered the first stem cell gene therapy. Their high patient volume directly correlates with more individualized treatment plans for rare or relapsed cases.
Patient Consensus: Patients note that institutional reputation in Milan or Rome matters as much as the individual doctor. They emphasize finding a specialist who leads a multidisciplinary board for personalized care.
Italian centers manage long-term Hodgkin lymphoma survivors through specialized hematology multidisciplinary teams. These programs follow Italian Lymphoma Foundation protocols. Surveillance focuses on detecting late effects. Survivors receive care at large research hospitals like San Raffaele in Milan. Monitoring ensures early detection of thyroid and cardiac issues.
Bookimed Expert Insight: Italian follow-up care is unique because it integrates cardio-oncology expertise directly into survivorship programs. San Raffaele surgeons and hematologists specialize in heart-vessel health and rare immune disorders. This is vital since survivors face higher lifelong cardiac risks after chest radiation or specific chemotherapies. Choosing an IRCCS-accredited research hospital ensures access to doctors like Professor Fabio Ciceri. He holds specialized memberships in both the Italian Society of Hematology and the International Cardio-Oncology Society.
Patient Consensus: Survivors highlight that care stays more consistent at major academic research hubs. Patients note it is vital to keep a written history of all treatments and drug doses.
Non-EU patients must obtain a Medical Treatment Visa (Visto per Cure Mediche) to enter Italy. This requires a formal hospital declaration and proof of an advance deposit. Applicants need confirmed travel bookings and Schengen medical insurance. Stays exceeding 90 days require a National Long-stay Visa.
Bookimed Expert Insight: Italian IRCCS-accredited centers like San Raffaele specialize in research and clinical assistance. These institutions handle over 50,000 operations yearly and are uniquely equipped for complex oncology administrative needs. Patients often secure faster approvals by coordinating through centers where physicians like Dr. Fabio Ciceri lead dedicated hematology units.
Patient Consensus: Patients note that medical documentation is the primary gatekeeper. Gathering translated records and securing the hospital confirmation letter are the most time-consuming steps for Italian entry.